



## **Eleison Pharmaceuticals Announces the Appointment of Murray Korc, MD, to its Science Advisory Board**

Princeton, NJ, December 16, 2010 -- Eleison Pharmaceuticals, Inc., a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, has announced the appointment of Dr. Murray Korc to the company's Science Advisory Board (SAB). Dr. Korc is Chair, Department of Medicine, Dartmouth Medical School, and is a widely-published expert in the molecular biology of pancreatic cancer.

"Past clinical data from glufosfamide in pancreatic cancer patients suggest that response to chemotherapy was affected by diabetic medications and the patient's metabolic condition; these may have therapeutic implications. Dr. Korc's expertise in both diabetes and pancreatic cancer makes him ideally suited to advise us on further studies with glufosfamide," said Forrest Anthony, MD, Chief Medical Officer and President of Eleison Pharmaceuticals.

Dr. Korc commented, "I am pleased to advise Eleison in investigating these metabolic interactions in their upcoming Phase III pivotal study in second-line metastatic pancreatic cancer."

### **About Dr. Murray Korc:**

Dr. Korc's primary research interests include the molecular biology of pancreatic cancer, abnormal gain of function through negative pathways, resistance of cancer cells to apoptosis, genetic mouse models of pancreatic cancer, tumor angiogenesis, and the role of microRNAs in pancreatic cancer. Most of the work in Dr. Korc's laboratory explores aberrant signaling pathways in cancer cells. In 2003, Dr. Korc joined the faculty at Dartmouth as Professor and Chair of Medicine and Professor of Pharmacology and Toxicology. Previously, he enjoyed faculty appointments at the UC Irvine Medical Center and at the University of Arizona. Dr. Korc completed his undergraduate studies at Brooklyn College and received his medical degree in 1974 from Albany Medical College.

### **About Eleison Pharmaceuticals:**

Eleison's mission is to acquire, develop, and commercialize clinical stage drug candidates for "orphan" indications, providing new hope for patients with rare life-threatening diseases. The Company plans to begin in mid-2011 a phase III clinical study of its lead drug candidate, glufosfamide, for pancreatic cancer. Founded in 2008 and headquartered in Princeton, NJ, Eleison is in discussions to acquire other promising programs for rare cancers

### **Forward Looking Statements**

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Eleison's product candidates, their uses and potential benefits and clinical trial results and plans. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Eleison's ability to enroll and complete its current and anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, the possibility that results from these trials will not be confirmed, potential adverse side effects, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Eleison does not intend to update any forward-looking statement made in this news release.

**SOURCE:** Eleison Pharmaceuticals, Inc.  
**CONTACT:** Eleison Pharmaceuticals, Inc.  
Corporate Communications  
103 Carnegie Center, Suite 300  
Princeton, NJ 08504  
215-416-7620  
[info@eleison-pharma.com](mailto:info@eleison-pharma.com)